Bulletin du cancer · 2026
[Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toledano Daniel, Chibaudel Benoist, Costa Jean-Marc, Boudabous Hanene, Coude Marie-Magdelaine, Luscan Armelle, Legrand Anne, Muller Etienne, Philippe Nicolas, Corbin Aurélie Driss, Ihout Paul, Squara Pierre, Lamallem Hanah, Dinet Emile, Pujol Pascal, Toledano Alain
Аннотация
BACKGROUND: Genetic counseling and molecular tumor boards have become essential components of oncology care pathways. Since 2012, a private-sector oncogenetics program supported by the National Cancer Institute (INCa), has been established within the Hauts-de-Seine health cooperation group, in connection with partner laboratories and a dedicated molecular tumor board.
METHODS: The study includes 10,071 oncogenetic consultations carried out between 2013 and 2024, and 1012 patients who underwent circulating tumor DNA (ctDNA) analysis between 2020 and 2024. Results were discussed in molecular and oncogenetic tumor boards.
RESULTS: The median delay for a first consultation was 3 weeks, compared to 10 weeks nationally. Mutation detection rates in hereditary breast-ovarian syndromes ranged from 11 to 16%, higher than the national average (8.8%). Among the 1012 ctDNA-tested patients, 411 (40%) presented actionable tumor alterations, including 284 (28%) classified as ESCAT I. Additional constitutional testing was triggered in 112 patients, revealing 27 unsuspected pathogenic variants (2.7%).
CONCLUSION: Private-practice oncogenetics and molecular tumor boards can achieve performance comparable to national indicators in terms of delays and mutation detection. The coordination between constitutional and tumor genetics activities enhances both therapeutic decisions and familial risk assessment.
METHODS: The study includes 10,071 oncogenetic consultations carried out between 2013 and 2024, and 1012 patients who underwent circulating tumor DNA (ctDNA) analysis between 2020 and 2024. Results were discussed in molecular and oncogenetic tumor boards.
RESULTS: The median delay for a first consultation was 3 weeks, compared to 10 weeks nationally. Mutation detection rates in hereditary breast-ovarian syndromes ranged from 11 to 16%, higher than the national average (8.8%). Among the 1012 ctDNA-tested patients, 411 (40%) presented actionable tumor alterations, including 284 (28%) classified as ESCAT I. Additional constitutional testing was triggered in 112 patients, revealing 27 unsuspected pathogenic variants (2.7%).
CONCLUSION: Private-practice oncogenetics and molecular tumor boards can achieve performance comparable to national indicators in terms of delays and mutation detection. The coordination between constitutional and tumor genetics activities enhances both therapeutic decisions and familial risk assessment.